Vitamin D, Oxidative Stress and Inflammation in Hemodialysis
Status:
Active, not recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
Vitamin D deficiency is now considered a global problem in general population, but it seemed
to be more prominent in chronic kidney disease (CKD) patients, especially those on regular
hemodialysis. Being a key regulator in mineral metabolism, there's also emerging evidences
linking vitamin D deficiency with inflammation and oxidative stress, which are both
recognized as constant threats to cardiovascular outcomes in hemodialysis patients.
It's prospective, randomized trial that's carried out to evaluate the effect of weekly
versus, monthly oral cholecalciferol, on vitamin D (25(OH)D) levels, oxidative stress
markers, inflammatory markers and secondary hyperparathyroidism in hemodialysis patients.
Fifty eligible hemodialysis patients were randomly assigned to either Group A (Oral 50.000IU
Cholecalciferol, once weekly) or Group B (Oral 200.000IU Cholecalciferol, once monthly), for
3 months. Serum levels of (25(OH)D), serum malondialdehyde (MDA), serum superoxide dismutase
(SOD), serum high sensitive (hsCRP), calcium, phosphorus, and intact parathormone (iPTH)
levels, were all assessed at baseline and at the end of the study